Brief: Barinthus Bio Presents Interim Data from Phase 2b HBV003 Trial and Phase 2a AB-729-202 Trial in Collaboration with Arbutus Biopharma in Chronic HBV Patients at AASLD
09/11/2023 22:10
Nov 9 (Reuters) - Barinthus Biotherapeutics PLC
2ABy.F :
* BARINTHUS BIO PRESENTS INTERIM DATA FROM PHASE 2B HBV003
TRIAL
AND PHASE 2A AB-729-202 TRIAL IN COLLABORATION WITH ARBUTUS
BIOPHARMA IN CHRONIC HBV PATIENTS AT AASLD
* BARINTHUS BIOTHERAPEUTICS PLC - VTP-300 WAS GENERALLY
WELL-TOLERATED IN BOTH TRIALS
Source text for Eikon: ID:nGNX6GRbP8
Further company coverage: 2ABy.F
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Barinthus Biotherapeutics
See all newsBrief: Barinthus Bio Provides Update On Proposed Combination With Clywedog Therapeutics
Brief: Barinthus Biotherapeutics PLC Appoints Douglas Swirsky As CFO And Principal Accounting Officer Effective May 1, 2026
Brief: Barinthus Bio Announces Update On Phase 1 AVALON Clinical Trial Of VTP-1000 For The Treatment Of Celiac Disease
Brief: Barinthus Bio Reports Second Quarter 2025 Financial Results And Updates On Corporate Developments
Gemma Brown Terminated As CFO Effective April 30, 2025 - SEC Filing